Expenditures for R&D from state government agencies increased by 17.3 percent from FY 2011 to FY 2016, reaching $2.3 billion, according to data from the Survey of State Government Research and Development, a survey sponsored by the National Science Foundation’s National Center for Science and Engineering Statistics (NCSES). Nearly two-thirds of this total – 64 percent – came from just five state governments (California, New York, Texas, Florida, and Ohio).
Today, the Greater Washington Partnership (the Partnership), a civic alliance of CEOs that together employ more than 175,000 workers in the region, released a new report that outlines why developing, attracting and retaining digital technology workers will be imperative for the Capital Region’s future growth and economic competitiveness.
The Emmes Corporation today announced its participation in a three-year study testing the results of two different opioid treatment medications. The research, published in one of the world’s oldest and best known medical journals, concluded that for those able to begin treatment, both drugs are nearly equal in their safety and effectiveness. The National Institute on Drug Abuse (NIDA) funded the research.
During the fall semester, students at Johns Hopkins who were interested in starting a company had some new options to turn to as they looked to develop their ideas and meet other entrepreneurs at the university.
Maryland is open for business and here’s another way our state supports companies seeking capital. Maryland Commerce has launched a new, searchable site that lets you search and find just the right program to fund your business. With the ability to filter by type of program, category or keyword, the Financial Incentives database is a great place to find grants, tax credits, loans and training. Give it a try!
The pharmaceutical industry as a whole is set to benefit from the tax reform vote to take place this week. The general reduction in corporate taxes and a special tax deduction for cash repatriated from overseas should see companies post improved returns to shareholders and a whole lot of cash freed up right away.
Are you worried about protecting your Intellectual Property? What about trademarks? How do you negotiate licenses? Have you thought through your patent strategy? How do you manage patents globally?
Learn about these issues and more from experts at Wilson Sonsini Goodrich & Rosati who will provide advice through 1:1 sessions at the Montgomery County Innovation Center in Rockville this Thursday, January 18th.
Preregistration by noon tomorrow, 1/17, REQUIRED. (Sessions filled on a first come-first served basis.)
The Food and Drug Administration has approved Mumbai-based Lupin’s Tydemy. The product is a generic version of Bayer’s Safyral (drospirenone, ethinyl estradiol, and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg).
A new research initiative by the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh could finally uncover how T-cells—the “killer cells” that defend the body from microbes—are alerted to hazardous invaders in the body. Funded by a $3.7 million grant from the National Institutes of Health (NIH), the research will be the first to combine X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy for a unique view of the cell’s alert system, which could lead to innovative therapeutics to fight viruses and tumors.
gel-e Inc., a privately held, clinical-stage medical device company, announces the 510(k) clearance of its adhesive bandage by the U.S. Food and Drug Administration (FDA) for prescription (Rx) and over-the-counter (OTC) use.
This new bandage clearance expands the Company’s label to include the management of moderately to heavily exuding chronic wounds and acute wounds. Under medical supervision, this new adhesive bandage may be used for the management of pressure sores, diabetic ulcers, leg ulcers, donor sites and graft sites, surgical wounds, skin abrasions and lacerations, 1st and 2nd degree burns and traumatic wounds. No medical supervision is required for usage in the management of minor cuts, minor scalds and 1st degree burns, and minor abrasions and lacerations. This newly cleared bandage complements gel-e’s existing vascular closure device cleared for the “management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.”
